Literature DB >> 35000559

Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States.

Otto Simonsson1,2,3, Simon B Goldberg1,4.   

Abstract

There are neurophysiological and phenomenological overlaps between psychedelic and meditative states, but there is little evidence on how exposure to psychedelics might be associated with meditation-related variables. We assessed lifetime classic psychedelic use, ego dissolution during one's most intense experience using a classic psychedelic, and exposure to meditation in a representative sample (n = 953) of American adults. Those who reported experience with meditation were invited to complete a follow-up survey (n = 536, 92.1% response rate) measuring meditation-related variables. Models controlled for a range of potential confounds. Exposure to meditation was associated with lifetime classic psychedelic use and ego dissolution in covariate-adjusted models. In addition, among meditators, greater ego dissolution was associated with more frequent meditation practice. Both lifetime classic psychedelic use and ego dissolution were associated with enlightenment as motivation to practice meditation as well as lower likelihood of overall perceived barriers to meditation practice. Ego dissolution was positively associated with finding meditation more effective. Neither lifetime classic psychedelic use nor ego dissolution was associated with greater likelihood of meditation-related adverse effects. Taken together, results support potential synergy between psychedelics and meditation, but randomized controlled trials are necessary to establish safety and evaluate potential causal relationships.

Entities:  

Keywords:  LSD; Psilocybin; Psychedelics; ego dissolution; meditation; mindfulness

Year:  2022        PMID: 35000559      PMCID: PMC9270502          DOI: 10.1080/02791072.2021.2022816

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  27 in total

1.  A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy.

Authors:  Jason B Luoma; Christina Chwyl; Geoff J Bathje; Alan K Davis; Rafael Lancelotta
Journal:  J Psychoactive Drugs       Date:  2020-06-12

2.  Psychedelics, Personality and Political Perspectives.

Authors:  Matthew M Nour; Lisa Evans; Robin L Carhart-Harris
Journal:  J Psychoactive Drugs       Date:  2017-04-26

3.  The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility.

Authors: 
Journal:  Addiction       Date:  2002-09       Impact factor: 6.526

4.  Assessing Perceived Barriers to Meditation: the Determinants of Meditation Practice Inventory-Revised (DMPI-R).

Authors:  Carly Ann Hunt; Mary Ann Hoffman; Jonathan J Mohr; Anna-Leila Williams
Journal:  Mindfulness (N Y)       Date:  2020-02-10

5.  The Current Status of Psychedelics in Psychiatry.

Authors:  David Nutt; Robin Carhart-Harris
Journal:  JAMA Psychiatry       Date:  2021-02-01       Impact factor: 21.596

Review 6.  The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant.

Authors:  Ben Sessa
Journal:  Psychopharmacology (Berl)       Date:  2017-08-23       Impact factor: 4.415

7.  Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat.

Authors:  Lukasz Smigielski; Michael Kometer; Milan Scheidegger; Rainer Krähenmann; Theo Huber; Franz X Vollenweider
Journal:  Sci Rep       Date:  2019-10-24       Impact factor: 4.379

8.  Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics.

Authors:  James D Sexton; Charles D Nichols; Peter S Hendricks
Journal:  Front Psychiatry       Date:  2020-02-11       Impact factor: 4.157

9.  Associations between lifetime classic psychedelic use and markers of physical health.

Authors:  Otto Simonsson; James D Sexton; Peter S Hendricks
Journal:  J Psychopharmacol       Date:  2021-03-09       Impact factor: 4.153

10.  Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.

Authors:  Alan K Davis; Frederick S Barrett; Darrick G May; Mary P Cosimano; Nathan D Sepeda; Matthew W Johnson; Patrick H Finan; Roland R Griffiths
Journal:  JAMA Psychiatry       Date:  2021-05-01       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.